Sort   by:  
 Page size 
UnknownLong-term pulmonary function in survivors of childhood cancer.

Purpose

This study was undertaken to determine the magnitude of pulmonary dysfunction in childhood cancer survivors when compared with healthy controls and the extent (and predictors) of decline over time.

Patients and methods

Survivors underwent baseline (t1) pulmonary function tests...
S-EPMC4417729 | biostudies-literature
UnknownCollaborative Research in Childhood Cancer Survivorship: The Current Landscape.
Survivors of childhood cancer carry a substantial burden of morbidity and are at increased risk for premature death. Furthermore, clear associations exist between specific therapeutic exposures and the risk for a variety of long-term complications. The entire landscape of health issues encountered f...
S-EPMC4567704 | biostudies-literature
UnknownLate Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.

Purpose

Given concerns that dexrazoxane may reduce treatment efficacy, induce second cancers, and thus compromise overall survival among children, we examined long-term overall and cause-specific mortality and disease relapse rates from three randomized clinical trials.

Patients and metho...

S-EPMC4534526 | biostudies-literature
UnknownCardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.

Purpose

To determine the oncologic efficacy, cardioprotective effectiveness, and safety of dexrazoxane added to chemotherapy that included a cumulative doxorubicin dose of 360 mg/m(2) to treat children and adolescents with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or lympho...
S-EPMC4872007 | biostudies-literature
UnknownCardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention.
Cardiovascular disease (CVD), which includes cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction, is a major concern for long-term survivors of childhood cancer. There is clear evidence of increased risk of CVD largel...
S-EPMC6804893 | biostudies-literature
UnknownCELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study.

Purpose

Interindividual variability in the dose-dependent association between anthracyclines and cardiomyopathy suggests that genetic susceptibility could play a role. The current study uses an agnostic approach to identify genetic variants that could modify cardiomyopathy risk.

Methods

S-EPMC5070560 | biostudies-literature
UnknownHyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group.

Purpose

The strong dose-dependent association between anthracyclines and cardiomyopathy is further exacerbated by the co-occurrence of cardiovascular risk factors (diabetes and hypertension). The high morbidity associated with cardiomyopathy necessitates an understanding of the underlying pa...
S-EPMC3927733 | biostudies-literature
Sort   by:  
 Page size